These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25782535)

  • 1. Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.
    Rabinovich-Guilatt L; Elgart A; Erisson L; Willsie SK; Tessler S; Barnett-Griness O; Pande A; Spiegelstein O
    Br J Clin Pharmacol; 2015 Sep; 80(3):436-45. PubMed ID: 25782535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects.
    Edwards AY; Elgart A; Farrell C; Barnett-Griness O; Rabinovich-Guilatt L; Spiegelstein O
    Br J Clin Pharmacol; 2017 Sep; 83(9):1932-1943. PubMed ID: 28294391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
    Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of QT Prolongation for 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects.
    Yu RZ; Gunawan R; Geary RS; Hughes SG; Henry SP; Wang Y
    Nucleic Acid Ther; 2017 Oct; 27(5):285-294. PubMed ID: 28799823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
    Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME
    J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
    Zielinski R; Chi KN
    Future Oncol; 2012 Oct; 8(10):1239-51. PubMed ID: 23130925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
    Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
    J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.
    Blumenstein B; Saad F; Hotte S; Chi KN; Eigl B; Gleave M; Jacobs C
    Cancer Med; 2013 Aug; 2(4):468-77. PubMed ID: 24156019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
    Glover JM; Leeds JM; Mant TG; Amin D; Kisner DL; Zuckerman JE; Geary RS; Levin AA; Shanahan WR
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1173-80. PubMed ID: 9316823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
    Han K; Cremer J; Elston R; Oliver S; Baptiste-Brown S; Chen S; Gardiner D; Davies M; Saunders J; Hamatake R; Losos J; Leivers M; Hood S; van der Berg F; Paff M; Ritter JM; Theodore D
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):790-801. PubMed ID: 30861337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous zanamivir on cardiac repolarization.
    Lou Y; Gan J; Peppercorn A; Gould E; Weller S; Piscitelli SC; Patel P
    Pharmacotherapy; 2013 Jul; 33(7):701-9. PubMed ID: 23553534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
    Sewell KL; Geary RS; Baker BF; Glover JM; Mant TG; Yu RZ; Tami JA; Dorr FA
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1334-43. PubMed ID: 12438559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
    Plummer R; Vidal L; Griffin M; Lesley M; de Bono J; Coulthard S; Sludden J; Siu LL; Chen EX; Oza AM; Reid GK; McLeod AR; Besterman JM; Lee C; Judson I; Calvert H; Boddy AV
    Clin Cancer Res; 2009 May; 15(9):3177-83. PubMed ID: 19383817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.